HomeCompareSQZ vs PLD

SQZ vs PLD: Dividend Comparison 2026

SQZ yields 459.77% · PLD yields 3.10%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SQZ wins by $32290.92M in total portfolio value
10 years
SQZ
SQZ
● Live price
459.77%
Share price
$0.44
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$32296.82M
Annual income
$22,619,113,625.24
Full SQZ calculator →
PLD
PLD
● Live price
3.10%
Share price
$132.18
Annual div
$4.10
5Y div CAGR
74.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$5.91M
Annual income
$4,750,725.19
Full PLD calculator →

Portfolio growth — SQZ vs PLD

📍 SQZ pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSQZPLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SQZ + PLD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SQZ pays
PLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SQZ
Annual income on $10K today (after 15% tax)
$39,080.46/yr
After 10yr DRIP, annual income (after tax)
$19,226,246,581.45/yr
PLD
Annual income on $10K today (after 15% tax)
$263.66/yr
After 10yr DRIP, annual income (after tax)
$4,038,116.41/yr
At 15% tax rate, SQZ beats the other by $19,222,208,465.04/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SQZ + PLD for your $10,000?

SQZ: 50%PLD: 50%
100% PLD50/50100% SQZ
Portfolio after 10yr
$16151.37M
Annual income
$11,311,932,175.21/yr
Blended yield
70.04%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PLD right now

SQZ
Analyst Ratings
4
Buy
1
Hold
1
Sell
Consensus: Buy
Price Target
$4.00
+819.5% upside vs current
Range: $4.00 — $4.00
Altman Z
-22.9
Piotroski
2/9
PLD
Analyst Ratings
25
Buy
16
Hold
1
Sell
Consensus: Buy
Price Target
$136.00
+2.9% upside vs current
Range: $119.00 — $155.00
Altman Z
1.9
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SQZ buys
0
PLD buys
0
No recent congressional trades found for SQZ or PLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSQZPLD
Forward yield459.77%3.10%
Annual dividend / share$2.00$4.10
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%74.4%
Portfolio after 10y$32296.82M$5.91M
Annual income after 10y$22,619,113,625.24$4,750,725.19
Total dividends collected$31438.26M$5.78M
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusBuyBuy
Analyst price target$4.00$136.00

Year-by-year: SQZ vs PLD ($10,000, DRIP)

YearSQZ PortfolioSQZ Income/yrPLD PortfolioPLD Income/yrGap
1← crossover$56,677$45,977.01$11,241$540.96+$45.4KSQZ
2$304,181$243,536.41$13,019$991.13+$291.2KSQZ
3$1,547,006$1,221,532.43$15,801$1,870.97+$1.53MSQZ
4$7,461,354$5,806,058.08$20,609$3,701.21+$7.44MSQZ
5$34,154,829$26,171,179.52$29,919$7,867.97+$34.12MSQZ
6$148,508,521$111,962,854.47$50,631$18,617.74+$148.46MSQZ
7$613,881,121$454,977,003.60$105,528$51,352.20+$613.78MSQZ
8$2,414,527,788$1,757,674,987.75$287,364$174,449.42+$2414.24MSQZ
9$9,044,589,126$6,461,044,393.43$1,081,760$774,280.77+$9043.51MSQZ
10$32,296,823,990$22,619,113,625.24$5,908,209$4,750,725.19+$32290.92MSQZ

SQZ vs PLD: Complete Analysis 2026

SQZStock

SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops cell therapies for patients with cancer, autoimmune, infectious diseases, and other serious conditions. Its lead product candidate is SQZ-PBMC-HPV, from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as a monotherapy and in combination with other immuno-oncology agents for the treatment of HPV16+ advanced or metastatic solid tumors, including cervical, head-and-neck, anal, penile, vulvar, and vaginal cancer. The company also develops SQZ-AAC-HPV, which is in a Phase I clinical trial for the treatment of HPV16+ advanced or metastatic solid tumors in monotherapy and in combinations with other immune-oncology agents. Its additional platforms in development are SQZ Activating Antigen Carriers; and SQZ Tolerizing Antigen Carriers. SQZ Biotechnologies Company was incorporated in 2013 and is headquartered in Watertown, Massachusetts.

Full SQZ Calculator →

PLDREIT

Prologis, Inc. is the global leader in logistics real estate with a focus on high-barrier, high-growth markets. As of December 31, 2020, the company owned or had investments in, on a wholly owned basis or through co-investment ventures, properties and development projects expected to total approximately 984 million square feet (91 million square meters) in 19 countries. Prologis leases modern logistics facilities to a diverse base of approximately 5,500 customers principally across two major categories: business-to-business and retail/online fulfillment.

Full PLD Calculator →
📬

Get this SQZ vs PLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SQZ vs SCHDSQZ vs JEPISQZ vs OSQZ vs KOSQZ vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.